Drug intelligence / Profile preview

APL-10456

Development stage: Phase 1
Lead developer: Apollo Therapeutics
Modality: Vaccines & Immunotherapeutics

Overview

APL-10456 is a prophylactic rhinovirus vaccine developed by Apollo Therapeutics to prevent exacerbations of major chronic lung conditions, such as chronic obstructive pulmonary disease (COPD) and asthma. It is designed to generate cross-species humoral and Th1-polarized cellular immunity against rhinovirus infections.

Targets

Human rhinovirus capsid protein

Beyond the preview

Go deeper on APL-10456.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APL-10456.

Explore the full profile